{"entity":{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","aka":["PGIMER","PGI Chandigarh"],"tldr":"PGIMER Chandigarh is the main tertiary referral hospital for north-west India and the regional cancer centre for Punjab and Haryana; its nuclear medicine department is among India's most active in PSMA and FAPI PET imaging and lutetium radioligand therapy.","summary":"PGIMER was established in 1962 and is the main tertiary referral centre for north-west India. Its oncology services span a regional cancer centre with radiotherapy and brachytherapy, medical and surgical oncology, and paediatric haematology-oncology, and its Department of Nuclear Medicine is among India's most active in PSMA and FAPI PET imaging and lutetium-based radioligand therapy. PGIMER researchers publish extensively on cervical cancer screening, gallbladder cancer, chronic myeloid leukaemia and cancer epidemiology in Punjab, and the institute leads the population cancer registries for the region and Indian cooperative trials.","asOf":"2026-09-09","links":[{"label":"PGIMER Chandigarh","url":"https://pgimer.edu.in"}],"tags":[],"related":[],"cancers":["prostate","cervical","cholangiocarcinoma","all-leukemia","neuroendocrine"],"sections":["radiopharma","radiation"],"technologies":["radioligand-therapy","psma-pet","fapi-pet","brachytherapy"],"targets":[],"drugs":["lutathera","pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["vivek-lal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chandigarh","country":"IN","lat":30.765,"lng":76.775,"institutionType":"hospital","website":"https://pgimer.edu.in","programs":["Nuclear medicine and theranostics","Radiotherapy and brachytherapy","Haematology","Cancer registry"]},"route":"/institutions/pgimer-chandigarh/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"person":[{"id":"vivek-lal","kind":"person","name":"Vivek Lal","route":"/people/vivek-lal/"}]}}